Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Canakinumab in Hereditary Periodic Fevers (CLUSTER)
NCT02059291Phase 3Completed
- Sponsor
- Novartis
- Start
- Jun 2014
- Primary completion
- Jul 2017
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 16
01
Overview
A Phase 3 trial of canakinumab in Familial Mediterranean fever (FMF), Hyperimmunoglobulinemia D with periodic fever syndrome (HIDS), Tumor necrosis factor receptor associated periodic syndrome (TRAPS), sponsored by Novartis. Started Jun 2014; status: completed.
02
Drugs
canakinumab
03
Conditions
Familial Mediterranean fever (FMF)Hyperimmunoglobulinemia D with periodic fever syndrome (HIDS)Tumor necrosis factor receptor associated periodic syndrome (TRAPS)
Beyond the preview
Go deeper on NCT02059291.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02059291.